The Preferred Biotech Resource in Asia-Pacific
Vol 19, No 07, July 2015
Biotech in China
Kh-biotech cover

Featured
Interviews

Eye on China

Columns

Conferences ListingConferences
Listing

e-alerts
Pharma Sales
INSIDE INDUSTRY
Quintiles honored as 'Best CRO in Asia' for 3rd time in four years

Quintiles was named the "Best CRO in Asia" at the 2014 BioPharma Asia Industry Awards dinner, the third time in the event's four-year history that Quintiles has received the honor. The award recognizes the contract research organization that has best demonstrated an ongoing commitment to improve clinical research in Asia and help customers succeed.

"This award reflects Quintiles' ability to improve our customers' probability of success by combining market knowledge with superior service," said Ken Lee, M.D., Quintiles Vice President and Regional General Manager for Southeast Asia, who accepted the award. "For 20 years we've been helping our customers navigate Asia's complex and changing healthcare environment. It's wonderful to be acknowledged for our excellence in bringing knowledge and people together for a healthier world."

In the last two years, Quintiles has continued to expand its integrated services in Asia-Pacific. Some of its services include:

  • Launching a late phase research offering, Real World and Late Phase Research, to help companies, governments and payers determine the value of new medicines in real-world use.
  • Significantly expanding its local CRO in China, Kun Tuo, which complements its global offering through Quintiles China.
  • Adding anatomic pathology, genomics and flow cytometry testing capabilities to its central laboratories in Singapore, Beijing, Tokyo and Mumbai, India.

Anand Tharmaratnam, M.D., Quintiles Senior Vice President and Head of Asia-Pacific, said of the award: "I'd like to dedicate to this to our employees, whose excellence made it possible; to our valued customers; and to patients worldwide whose lives and quality of life depend on new and better medicines."

Click here for the complete issue.